peppersite
Protocol_component

CJC-1295 / Ipamorelin (No Dac)

CJC-1295Ipamorelin

This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.

A blend, not a compound

This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.

Researched for
Recovery

At a glance

Also called
CJC-1295 5mg / Ipamorelin 5mg (No Dac) 10mg
Type
Protocol component
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
Sources differ. See the source

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

The reference does not report a single injectable amount for CJC-1295 / Ipamorelin (No Dac), so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 / Ipamorelin (No Dac) or for anything else, and nothing below has been checked against the study it came from.

200-300 mcg of each peptide daily, typically administered once daily SubQ.
Frequency
not stated
Route
not stated
Reported by
Peptide Dosing Protocols stack
Reconstitution, as reported
  • Add 3.0 mL BAC water to a 20 mg blend vial.
Not yet audited

We have not published an audit on CJC-1295 / Ipamorelin (No Dac). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

One part tells the pituitary gland to make growth hormone, and the other tells the same cells to release it, through a completely separate receptor. Researchers link this to the GHRH receptor on pituitary somatotrophs and the ghrelin receptor (GHSR1a); a 2002 study by Cunha and Mayo in Endocrinology reported that ghrelin-receptor signalling strengthens GHRH signalling on the same cell, so the two multiply rather than add. The no-DAC form is the one paired here because its 30-minute to 2-hour half-life matches Ipamorelin's roughly 2-hour half-life and keeps release in natural pulses. No published human randomised trial has tested the combination at the daily 200-300 mcg doses common in research planning, and FDA review documents from October 2024 noted the limited clinical data.

Reported side effects

Reported by users: facial flushing or warmth in the first 5-10 minutes after an injection, described as more common with CJC-1295 than Ipamorelin; mild water retention in the first 1-2 weeks of a cycle that often settles; vivid dreams or deeper sleep; a small rise in hunger 20-30 minutes after Ipamorelin, less marked than with GHRP-6; and mild irritation where it is injected.

Not ruled out: because no human trial has tested the pair, these summaries are carried over from the single compounds and from supervised clinic use of similar pairings, and long-term data past 90 days is limited even for the single compounds. Tingling or numbness in the hands is described as a sign of too much growth hormone or IGF-1; blood sugar can shift because growth hormone works against insulin; joint pain past the first two weeks is flagged; FDA review documents named rare allergic-type reactions; and long-term stimulation studies have flagged an underactive thyroid in a minority. Product quality varies between research suppliers, with a batch-matched certificate of analysis described as the minimum quality signal.

Who should avoid it

People with active cancer, a past cancer, or unscreened tumors: growth hormone and IGF-1 encourage cells to divide.

People with pituitary disease: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.

People with diabetic retinopathy: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.

People with severe kidney disease: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.

People who are pregnant or breastfeeding: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.

People with diabetes, insulin resistance or pre-diabetes: growth hormone works against insulin, so blood sugar needs close watching.

People with a known hypersensitivity to these peptides: FDA review documents named rare allergic-type reactions for both.

People with a thyroid condition: long-term growth hormone stimulation studies have flagged an underactive thyroid in a minority of users.

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things